School of Pharmacy, Monash University Malaysia, Jalan Lagoon Selatan, 47500 Subang Jaya, Bandar Sunway, Selangor, Malaysia.
Centre for Inflammation, Centenary Institute and University of Technology Sydney, Faculty of Science, School of Life Sciences, Sydney, NSW, 2007, Australia.
Environ Sci Pollut Res Int. 2022 Aug;29(36):54072-54087. doi: 10.1007/s11356-022-20984-7. Epub 2022 Jun 3.
Coronavirus disease 2019 (COVID-19) is an infectious disease associated with the respiratory system caused by the SARS-CoV-2 virus. The aim of this review article is to establish an understanding about the relationship between autoimmune conditions and COVID-19 infections. Although majority of the population have been protected with vaccines against this virus, there is yet a successful curative medication for this disease. The use of autoimmune medications has been widely considered to control the infection, thus postulating possible relationships between COVID-19 and autoimmune diseases. Several studies have suggested the correlation between autoantibodies detected in patients and the severity of the COVID-19 disease. Studies have indicated that the SARS-CoV-2 virus can disrupt the self-tolerance mechanism of the immune system, thus triggering autoimmune conditions. This review discusses the current scenario and future prospects of promising therapeutic strategies that may be employed to regulate such autoimmune conditions.
新型冠状病毒病(COVID-19)是一种与呼吸系统相关的传染病,由 SARS-CoV-2 病毒引起。本文的目的是了解自身免疫性疾病与 COVID-19 感染之间的关系。尽管大多数人已经通过疫苗接种对该病毒具有免疫力,但目前尚无针对该疾病的有效治疗药物。人们广泛认为使用自身免疫性药物可以控制感染,因此推测 COVID-19 和自身免疫性疾病之间可能存在关联。几项研究表明,在 COVID-19 患者中检测到的自身抗体与疾病的严重程度之间存在相关性。研究表明,SARS-CoV-2 病毒可以破坏免疫系统的自身耐受机制,从而引发自身免疫性疾病。本文讨论了当前的情况和未来有前景的治疗策略的前景,这些策略可能被用于调节这些自身免疫性疾病。